KROKronos Worldwide, Inc.
Is the price fair?
In its normal P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In its normal range: P/E 10.1 vs a 10.3 median over 26 quarters (−2% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What KRO's price assumes
Kronos Worldwide, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.37× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 0.97
Price / book · as of 2026-Q2
- EV / sales
- 0.65
EV / sales
Details›
- Price / bookas of 2026-Q2
- 0.97
- EV / EBIToperating margin −1.7%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 0.65
- Market capitalisation115.1 million shares, counted Jul 31, 2026
- $899M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Specialty Chemicals
Ranks #29 of 33 by RyuScore